EQS-Adhoc: Merck KGaA: Evobrutinib erreicht primären Endpunkt der Verringerung der annualisierten Schubraten (ARR) im Vergleich zu oralem Teriflunomid in Phase-III-Studien nicht
|
EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Studienergebnisse Darmstadt, 5. Dezember 2023: Die Merck KGaA erforscht einen oralen, hochselektiven, das zentrale Nervensystem penetrierenden Inhibitor der Brutontyrosinkinase ("BTKi") als potenzielle Behandlung für schubförmige Multiple Sklerose ("RMS") in zwei zulassungsrelevanten klinischen Phase-III-Studien (evolutionRMS 1 und evolutionRMS 2, zusammen die „Klinischen Studien“). Beide Klinischen Studien, welche die Sicherheit und Wirksamkeit von Evobrutinib im Vergleich zu Teriflunomid über einen Zeitraum von bis zu 156 Wochen überprüfen, haben ihren primären Endpunkt der Verringerung der annualisierten Schubraten (ARR) bei RMS nicht erreicht.
Evobrutinib befindet sich derzeit in der klinischen Prüfung und ist weltweit in keiner Indikation zugelassen. Esther Döringer Merck KGaA Frankfurter Straße 250 64293 Darmstadt Deutschland Tel.: +49 151 1454 7809 E-Mail: esther.doeringer@merckgroup.com Internet: https://www.merckgroup.com/de ISIN: DE0006599905 WKN: 659990 Indizes: DAX Börsen: Regulierter Markt in Frankfurt am Main (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; Terminbörse EUREX; London, SIX Ende der Insiderinformation
05.12.2023 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
| Sprache: | Deutsch |
| Unternehmen: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Deutschland | |
| Telefon: | +49 (0)6151 72 - 2702 |
| E-Mail: | Friederike.Segeberg@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indizes: | DAX |
| Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1790011 |
| Ende der Mitteilung | EQS News-Service |
|
|
1790011 05.12.2023 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 14.836,00 | 16.152,00 | 17.534,00 | 19.687,00 | 22.232,00 | 20.993,00 | 21.390,00 | |
| EBITDA1,2 | 3.528,00 | 4.066,00 | 4.923,00 | 5.946,00 | 6.504,00 | 5.489,00 | 5.850,00 | |
| EBITDA-Margin3 | 23,78 | 25,17 | 28,08 | 30,20 | 29,26 | 26,15 | 27,35 | |
| EBIT1,4 | 1.727,00 | 2.120,00 | 2.985,00 | 4.179,00 | 4.474,00 | 3.609,00 | 3.985,00 | |
| EBIT-Margin5 | 11,64 | 13,13 | 17,02 | 21,23 | 20,12 | 17,19 | 18,63 | |
| Net Profit (Loss)1 | 3.396,00 | 1.324,00 | 1.994,00 | 3.065,00 | 3.339,00 | 2.834,00 | 2.890,00 | |
| Net-Margin6 | 22,89 | 8,20 | 11,37 | 15,57 | 15,02 | 13,50 | 13,51 | |
| Cashflow1,7 | 2.219,00 | 2.856,00 | 3.477,00 | 4.616,00 | 4.259,00 | 3.784,00 | 0,00 | |
| Earnings per share8 | 7,76 | 3,04 | 4,57 | 7,03 | 7,65 | 6,49 | 6,65 | |
| Dividend per share8 | 1,25 | 1,30 | 1,40 | 1,85 | 2,20 | 2,20 | 2,40 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Merck | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 659990 | DE0006599905 | KGaA | 60.086,30 Mio € | 20.10.1995 | Halten | 8FXCVMW3+5C |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 17,95 | 24,92 | 0,72 | 24,79 | 2,28 | 15,88 | 2,86 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 2,20 | 2,20 | 2,40 | 1,74% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.04.2025 | 15.05.2024 | 01.08.2024 | 14.11.2024 | 06.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,30% | -12,30% | -4,09% | -2,19% | +901,45% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
